“Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies”, J Clin Oncol, vol. 40, no. 4, pp. 356-368, 2022.
, “Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.”, Blood, vol. 124, no. 22, pp. 3221-7; quiz 3335, 2014.
, “Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials ne”, Biol Blood Marrow Transplant, vol. 20, no. 6, pp. 858-64, 2014.
, “Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302.”, Biol Blood Marrow Transplant, vol. 19, no. 3, pp. 481-5, 2013.
, “Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study.”, Blood, vol. 119, no. 16, pp. 3854-60, 2012.
, “Phase II trial of parathyroid hormone after double umbilical cord blood transplantation.”, Biol Blood Marrow Transplant, vol. 18, no. 12, pp. 1851-8, 2012.
, ,
“Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.”, Blood, vol. 112, no. 12, pp. 4425-31, 2008.
, “Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation.”, Biol Blood Marrow Transplant, vol. 11, no. 8, pp. 571-5, 2005.
,